Stay up to date with the latest announcements, product launches, conference participations, and corporate milestones from Shomam Pharma.
Our proprietary SoluMax™ bioavailability platform enables a new high-dose atorvastatin formulation with improved dissolution profile, now available across domestic and select export markets.
Read more
Following a successful pre-approval inspection of our Pune facility, the USFDA has granted approval for our Metformin ER 1000mg ANDA, opening the US generics market for this key diabetes therapy.
Read more
Our team presented the latest additions to our API and finished dosage form portfolio at CPhI Worldwide in Milan. Over 200 partnering meetings were held with distributors and licensing partners from 45 countries.
Read more
We are honoured to receive the Best Pharmaceutical Exporter award at the India Pharma Awards 2026, recognising our consistent quality standards and growing global footprint across 60+ countries.
Read more
Construction of our third manufacturing block at the Pune campus is complete. The new facility adds 2 billion tablets per annum of oral solid dosage capacity and is WHO-GMP certified.
Read more
Shomam Pharma has launched its NanoShield™-based oncology support portfolio — including anti-emetics, colony-stimulating factors, and supportive care products — across Malaysia, Thailand, and Vietnam.
Read more
Our R&D team presented three posters on hot-melt extrusion and lipid-based drug delivery at AAPS PharmSci 360 in Washington DC, generating significant interest from global pharmaceutical partners.
Read more
We have entered into a co-development and licensing agreement with a leading European specialty pharmaceutical company for three modified-release products targeting the EU and UK markets.
Read moreOur proprietary SoluMax™ bioavailability platform enables a new high-dose atorvastatin formulation with improved dissolution profile, now available across domestic and select export markets.
Read moreFollowing a successful pre-approval inspection of our Pune facility, the USFDA has granted approval for our Metformin ER 1000mg ANDA, opening the US generics market for this key diabetes therapy.
Read moreOur team presented the latest additions to our API and finished dosage form portfolio at CPhI Worldwide in Milan. Over 200 partnering meetings were held with distributors and licensing partners from 45 countries.
Read moreWe are honoured to receive the Best Pharmaceutical Exporter award at the India Pharma Awards 2026, recognising our consistent quality standards and growing global footprint across 60+ countries.
Read moreConstruction of our third manufacturing block at the Pune campus is complete. The new facility adds 2 billion tablets per annum of oral solid dosage capacity and is WHO-GMP certified.
Read moreShomam Pharma has launched its NanoShield™-based oncology support portfolio — including anti-emetics, colony-stimulating factors, and supportive care products — across Malaysia, Thailand, and Vietnam.
Read moreOur R&D team presented three posters on hot-melt extrusion and lipid-based drug delivery at AAPS PharmSci 360 in Washington DC, generating significant interest from global pharmaceutical partners.
Read moreWe have entered into a co-development and licensing agreement with a leading European specialty pharmaceutical company for three modified-release products targeting the EU and UK markets.
Read moreIndia's largest pharmaceutical trade exhibition. Visit our booth to explore our full product portfolio and meet our business development team.
Schedule a meetingThe premier pharma ingredients and finished dosage form event in South Asia. Schedule a partnering meeting with our team in advance.
Schedule a meetingAnnual gathering of pharmaceutical business development and licensing professionals. Our BD team will be available for one-on-one meetings.
Schedule a meetingSubscribe to receive Shomam Pharma news, product launches, and event invitations directly in your inbox.
